Investigator Perspectives

Aaron Gerds, MD, MS, provides an overview of myelofibrosis and its changing treatment landscape.

Expert hematologist Stephen Oh, MD, PhD, provides an overview of myelofibrosis, and discusses how new data from ASH 2022 affect the treatment landscape.

Lori Wirth, MD, provides an overview of radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC), the standard-of-care treatment options, and the importance of testing for molecular alterations in patients with RAI-R-DTC.

Rana McKay, MD discusses emerging data in the metastatic renal cell carcinoma treatment landscape, reviewing the current standard of care and then delving into recent data updates from the CheckMate 9ER and COSMIC-313 trials.

Lori Wirth, MD, reviews real-world and clinical trial data on treatment of advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC) with lenvatinib, and her personal experience with lenvatinib in clinical practice.

Edward B. Garon, MD, MS, provides his expert perspective on immune checkpoint inhibition in metastatic non-small cell lung cancer (mNSCLC) and evaluates the currently available immunotherapy combinations.

Dr Aditya Bardia reviews the potential role of elacestrant for the treatment of metastatic ER+/HER2- breast cancer, starting with an overview of the current landscape and focusing specifically on key efficacy data from the EMERALD Trial.

Naveen Pemmaraju, MD, explains the types of myeloproliferative neoplasms, the currently available treatment options, and how treatment approaches have changed historically.

Robert Zeiser, MD, discusses the landscape of graft versus host disease and reviews data related to the current treatment options.

Courtney DiNardo, MD, discusses the use of venetoclax in newly-diagnosed acute myeloid leukemia, with a review of data from the VIALE-A clinical trial.

Naveen Pemmaraju, MD, provides his expert perspective on currently available treatment options in myelofibrosis and data from the REFINE trial on the experimental therapy of ruxolitinib plus navitoclax.

Scott Tagawa, MD, MS, FACP, comments on treatment and management strategies in metastatic castration-resistant prostate cancer (CRPC), and reviews recent data on the VISION trial of Lu 177 vipivotide tetraxetan.

Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Moshe Ornstein, MD.

Expert gynecologic oncologist Brian Slomovitz, MD, MS, FACOG, shares insight on novel therapeutic approaches to the management of endometrial cancer.

David M. O’Malley, MD, explores the use of PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of recurrent/metastatic cervical cancer.

Expert perspective from Anthony B. El-Khoueiry, MD, who reviews the evolving treatment landscape of targeted therapy for advanced/metastatic cholangiocarcinoma.

Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Memorial Sloan Kettering Cancer Center’s Chung-Han Lee, MD, PhD, and Kiran Kehoe, RN, BSN, CCRN.

Mary F. Mulcahy, MD, breaks down the phase III EPOCH study and explains how it has affected the treatment of colorectal cancer with liver metastasis.

Scott T. Tagawa, MD, FACP, reviews the use of 177Lu-PSMA-617 radioligand therapy and clinical implications from the phases 3 VISION trial for patients with metastatic castration-resistant prostate cancer (mCRPC).

Karim Fizazi, MD, PhD, provides a discussion on metastatic castrate-resistant prostate cancer and the use of darolutamide for management.

Considerations for updated data from the MAIA study of daratumumab plus lenalidomide and dexamethasone, and how they fit into the optimal management of transplant-ineligible newly diagnosed multiple myeloma.

Daniel Pollyea, MD, MS, discusses the current treatment options for acute myeloid leukemia.

Naval Daver, MD, explains the current and emerging treatment options for myelodysplastic syndrome.

John Marshall, MD, discusses the realities of metastatic colorectal cancer management and therapy options to consider outside of chemotherapy—regorafenib, in particular.

Sarat Chandarlapaty, MD, discusses the treatment landscape of metastatic ER+/HER2- breast cancer, including observations made from the results of the AMEERA-1 trial and the use of amcenestrant as a therapy option.

Evan Y. Yu, MD, reviews the use of LuPSMA radioligand therapy and the role of precision medicine in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Expert reflections on the optimal identification and management of unresectable hepatocellular carcinoma given recent updates from the IMbrave150 trial.

In this Investigator Perspectives, Yi-Bin Chen, MD discusses the difference between acute and chronic graft versus host disease, the initial therapeutic management of these diseases, and the newly-approved agents for steroid-refractory disease. He also provides his insights regarding future directions and unmet needs for steroid-refractory GVHD.

An expert in hematology-oncology provides key insights into treatment considerations for patients with hepatocellular carcinoma and reviews safety and efficacy data from the phase 3 REFLECT Trial of lenvatinib for patients with unresectable disease.

Andrew J. Armstrong, MD, MSc, evaluates the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.